Table 2.
Outcome variable | Heparin cohort (matched) (n = 778) | Enoxaparin cohort (matched) (n = 778) | BH‐adjusted p value | Relative risk (95% confidence interval [CI]) Heparin versus enoxaparin |
---|---|---|---|---|
Number of patients with reported outcomes | ||||
|
733 | 711 | ||
|
463 | 528 | ||
|
732 | 714 | ||
|
328 | 393 | ||
|
159 | 199 | ||
|
758 | 742 | ||
Mortality at hospital discharge | 268/733 (37%) | 154/711 (22%) | 1.5e−8 | 1.69 (1.42, 2.00) |
Mortality at 28 days | 44/463 (9.5%) | 12/528 (2.3%) | 1.3e−5 | 4.18 (2.19, 7.51) |
ICU admission during hospitalization | 481/732 (66%) | 399/714 (56%) | 8.8e−4 | 1.18 (1.08, 1.28) |
Hospital length of stay (days) | 12.7 (12.2) | 11.7 (10.3) | .88 | |
ICU length of stay (days) | 12.3 (11.7) | 10.9 (10.3) | .47 | |
Complications during hospitalization | ||||
|
39 (5.1%) | 18 (2.4%) | .03 | 2.12 (1.21, 3.60) |
|
280 (37%) | 182 (25%) | 2.9E−06 | 1.51 (1.29, 1.76) |
|
224 (30%) | 200 (27%) | .47 | 1.10 (0.93, 1.29) |
|
101 (13%) | 70 (9.4%) | .07 | 1.41 (1.06, 1.88) |
|
49 (6.5%) | 35 (4.7%) | .35 | 1.37 (0.90, 2.08) |
|
94 (12%) | 95 (13%) | .92 | 0.97 (0.74, 1.26) |
|
74 (9.8%) | 65 (8.8%) | .73 | 1.11 (0.81, 1.53) |
|
54 (7.1%) | 50 (6.7%) | .92 | 1.06 (0.73, 1.53) |
|
59 (7.8%) | 53 (7.1%) | .87 | 1.09 (0.76, 1.55) |
|
28 (3.7%) | 14 (1.9%) | .12 | 1.96 (1.03, 3.59) |
|
23 (3%) | 21 (2.8%) | .94 | 1.07 (0.60, 1.90) |
|
76 (10%) | 103 (14%) | .07 | 0.72 (0.55, 0.96) |
|
59 (7.8%) | 47 (6.3%) | .47 | 1.23 (0.85, 1.77) |
|
36 (4.7%) | 24 (3.2%) | .35 | 1.47 (0.88, 2.41) |
|
144 (19%) | 95 (13%) | .01 | 1.48 (1.17, 1.88) |
|
19 (2.5%) | 11 (1.5%) | .40 | 1.69 (0.81, 3.42) |
|
111 (15%) | 119 (16%) | .68 | 0.91 (0.72, 1.16) |
Note: Summary of clinical outcomes for matched cohorts of hospitalized COVID‐19 patients who have taken either unfractionated heparin or enoxaparin (but not both). For categorical variables, such as mortality status and complications, patient counts are shown with the percentage of each cohort in parentheses. Only patients with reported outcomes in each cohort are used to determine the percentages. For numeric variables, such as hospital and ICU length of stay, the mean value for each cohort is shown with standard deviation in parentheses. In addition, Benjamini–Hochberg adjusted p values are shown for the statistical tests comparing the outcome variables for the matched enoxaparin and Heparin cohorts; relative risk of outcomes (heparin relative to enoxaparin) are shown as well, along with 95% CI.
Abbreviations: ARDS, acute respiratory distress syndrome; COVID‐19, coronavirus disease 2019; ICU, intensive care unit.